388 related articles for article (PubMed ID: 25575541)
1. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.
Zhou H; Xu M; Qin P; Zhang HY; Yuan CL; Zhao HG; Cui ZG; Meng YS; Wang L; Zhou F; Wang X; Li DQ; Bi KH; Zhu CS; Guo CS; Chu XX; Wu QC; Liu XG; Dong XY; Li J; Peng J; Hou M
Blood; 2015 Mar; 125(10):1541-7. PubMed ID: 25575541
[TBL] [Abstract][Full Text] [Related]
2. All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP.
Wu YJ; Liu H; Zeng QZ; Liu Y; Wang JW; Wang WS; Jia-Feng ; Zhou HB; Huang QS; He Y; Fu HX; Zhu XL; Jiang Q; Jiang H; Chang YJ; Xu LP; Huang XJ; Zhang XH
Blood; 2022 Jan; 139(3):333-342. PubMed ID: 34665865
[TBL] [Abstract][Full Text] [Related]
3. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial.
Yu Y; Wang M; Hou Y; Qin P; Zeng Q; Yu W; Guo X; Wang J; Wang X; Liu G; Chu X; Yang L; Feng Y; Zhou F; Sun Z; Zhang M; Wang X; Wang Z; Ran X; Zhao H; Wang L; Zhang H; Bi K; Li D; Yuan C; Xu R; Wang Y; Zhou Y; Peng J; Liu XG; Hou M
Am J Hematol; 2020 Dec; 95(12):1542-1552. PubMed ID: 32871029
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP.
Li Y; Wang YY; Fei HR; Wang L; Yuan CL
Eur Rev Med Pharmacol Sci; 2015; 19(9):1583-8. PubMed ID: 26004596
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study.
Liu X; Bai Y; Wang T; Song Y; Sun F; Xia R; Zhu F; Ma J; Lu Q; Ye X; Zhan X; Li L; Guo X; Cheng S; Li Y; Guo Z; Chen Y; Qian S; Qin L; Zhang Q; Cao S; Yang R
Platelets; 2023 Dec; 34(1):2157806. PubMed ID: 36597010
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z
Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414
[TBL] [Abstract][Full Text] [Related]
7. Anti-GPIb/IX autoantibodies are associated with poor response to dexamethasone combined with rituximab therapy in primary immune thrombocytopenia patients.
Ding B; Liu L; Li M; Song X; Zhang Y; Xia A; Liu J; Zhou H
Platelets; 2023 Dec; 34(1):2258988. PubMed ID: 37722393
[TBL] [Abstract][Full Text] [Related]
8. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia.
Cui ZG; Liu XG; Qin P; Hou M; Wu SL; Peng J; Zhao HG; Wang HY; Zhao CT
Chin Med J (Engl); 2013 Nov; 126(21):4145-8. PubMed ID: 24229688
[TBL] [Abstract][Full Text] [Related]
10. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy.
Kong Z; Qin P; Xiao S; Zhou H; Li H; Yang R; Liu X; Luo J; Li Z; Ji G; Cui Z; Bai Y; Wu Y; Shao L; Peng J; Ma J; Hou M
Blood; 2017 Aug; 130(9):1097-1103. PubMed ID: 28630121
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
[TBL] [Abstract][Full Text] [Related]
12. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia.
Wang S; Yang R; Zou P; Hou M; Wu D; Shen Z; Lu X; Li Y; Chen X; Niu T; Sun H; Yu L; Wang Z; Zhang Y; Chang N; Zhang G; Zhao Y
Int J Hematol; 2012 Aug; 96(2):222-8. PubMed ID: 22753022
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of recombinant human thrombopoietin combined with high-dose dexamethasone in the treatment of refractory immune thrombocytopenia in children].
Lu YY; Guan N; Meng QH; Li ML; Liu YY; Wang Y
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jul; 20(7):534-537. PubMed ID: 30022753
[TBL] [Abstract][Full Text] [Related]
14. ITP and TTP: interpreting evidence in light of patient values.
Cuker A
Blood; 2015 Mar; 125(10):1514-5. PubMed ID: 25745181
[TBL] [Abstract][Full Text] [Related]
15. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
[No Abstract] [Full Text] [Related]
16. [Clinical analysis of recombinant humanized thrombopoietin for treating 25 children with severe immune thrombocytopenia].
Zheng J; Ma JY; Su Y; Yang J; Zhang RD; Zhou X; Wu RH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):393-8. PubMed ID: 24763011
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression.
Yang ZG; Wen RT; Zhang YM; Wu GC; Chen WJ; Wang YF; Weng ZY; Wen SS; Zhang XJ; Guan MH
Int Immunopharmacol; 2019 Jul; 72():437-444. PubMed ID: 31030100
[TBL] [Abstract][Full Text] [Related]
18. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of recombinant human thrombopoietin in adult patients with primary immune thrombocytopenia during the perioperative period].
Sun HP; Hu Q; You JH; Chen QS; Wang J; Li JM; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):191-194. PubMed ID: 30929384
[No Abstract] [Full Text] [Related]
20. [Efficacy and safety of rhTPO in the treatment of pediatric primary immune thrombocytopenia].
Huang Y; Liu X; Xue F; Chen Y; Liu W; Fu R; Zhang L; Yang R
Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):511-4. PubMed ID: 26134019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
